Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05975424 · ClinicalTrials.gov registry record

LTFU Study of Subjects With Cervical SCI Who Received AST-OPC1

A clinical trial of Spinal Cord Injuries, sponsored by Lineage Cell Therapeutics.

Active
Registry status
25
Enrollment target
6
Study locations

NCT05975424: Active study of Spinal Cord Injuries, sponsored by Lineage Cell Therapeutics.

NCT05975424 is a study of Spinal Cord Injuries that is active but no longer recruiting, run by Lineage Cell Therapeutics. The registered enrollment target is 25 participants, below the 61-participant average among 202 other Spinal Cord Injuries trials with a reported enrollment target (59% lower). The trial reports 6 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05975424, a study of Spinal Cord Injuries, is active but no longer recruiting, sponsored by Lineage Cell Therapeutics.

ACTIVE NOT RECRUITING
Registry status
25 participants
Enrollment target
6
Study locations

Study Summary

This is a LTFU study for cervical SCI subjects that were administered AST-OPC1 cells in the main study AST-OPC1-01.

Primary Outcome

Information will be collected on all adverse events through Year 5 and on late-occurring adverse events (Years 6-15) related to any changes in neurological condition, a fever of unknown etiology, and the development of neoplasias and/or neurological disorders.

Conditions Studied

Interventions

  • DIAGNOSTIC_TEST Magnetic Resonance Imaging (MRI)

Study Locations (6)

California

  • University of Southern California - Los Angeles
  • Stanford University - Palo Alto

Georgia

  • Shepherd Center - Atlanta

Illinois

  • RUSH University Medical Center - Chicago

Pennsylvania

  • Thomas Jefferson University - Philadelphia

Wisconsin

  • Medical College of Wisconsin - Milwaukee

Trial Details

FieldValue
Enrollment Target 25 participants
Start Date 2018-06-13
Est. Completion 2033-01-14
Lineage Cell Therapeutics

5 total trials

What the registry record for NCT05975424 still lists

NCT05975424 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 25 participants, a relatively small participant target, below the 61-participant average among 202 other Spinal Cord Injuries trials with a reported enrollment target (59% lower).

The record links to 1 condition, with Spinal Cord Injuries appearing as the primary indexed condition, and to 1 intervention - of which Magnetic Resonance Imaging (MRI) is the first listed.

NCT05975424 lists 6 locations in 5 states (California, Georgia, Illinois).

Frequently Asked Questions

What is clinical trial NCT05975424 about?

NCT05975424 is a clinical study titled "LTFU Study of Subjects With Cervical SCI Who Received AST-OPC1". This is a LTFU study for cervical SCI subjects that were administered AST-OPC1 cells in the main study AST-OPC1-01.

What is the current status of trial NCT05975424?

This trial is currently active not recruiting. The enrollment target is 25 participants. The study started on 2018-06-13. Estimated completion is 2033-01-14.

What conditions does trial NCT05975424 study?

This clinical trial studies the following conditions: Spinal Cord Injuries.

What interventions are being tested in trial NCT05975424?

The interventions under investigation include: Magnetic Resonance Imaging (MRI) (DIAGNOSTIC_TEST).

Who is sponsoring clinical trial NCT05975424?

This trial is sponsored by Lineage Cell Therapeutics, which has 5 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05975424 being conducted?

This trial has 6 study locations across California, Georgia, Illinois, Pennsylvania, Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Spinal Cord Injuries

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05975424's enrollment target sits among peer trials

25 110th of 202 higher than 90 of 202 other Spinal Cord Injuries trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Spinal Cord Injuries trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01166854 · 25 participants

    Characterization of Familial Myopathy and Paget Disease of Bone

  • NCT01913106 · 25 participants · Phase 1

    HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer

  • NCT02138669 · 25 participants · NA

    Intacs Prescription Inserts for Keratoconus Patients

  • NCT02174549 · 25 participants · Phase 1

    Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT06358040 · started 2026-10 · NA

    Opioid Dispenser for Microdiscectomy/Laminectomy

Source: ClinicalTrials.gov NCT05975424, the US trial registry maintained by the National Library of Medicine. NCT05975424 (small enrollment · multi site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.